GlassScriptPhysician profile
Cheryl Renee Eldridge
NPI 1235620071
$1,998.22
in general payments reported to CMS, 2019-2025
22 companies · $615 in 2025
The $615 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $118 · 2022: $279 · 2023: $624 · 2024: $361 · 2025: $615.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,601.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,600.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $850.75 | 2021-2025 | |
| Lilly USA, LLC | $180.63 | 2022-2025 | Jardiance, Mounjaro, Emgality |
| Novo Nordisk INC | $166.15 | 2022-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $105.95 | 2022-2024 | Trelegy Ellipta, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $75.95 | 2022-2025 | Xifaxan, Trulance |
| Axsome Therapeutics, INC. | $72.66 | 2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $68.02 | 2023 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.03 | 2023-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $54.98 | 2023-2024 | Airsupra |
| Abbott Laboratories | $54.64 | 2022-2025 | Freestyle Libre 3 |
| Bausch Health US, LLC | $43.09 | 2022 | |
| Xeris Pharmaceuticals, INC. | $42.02 | 2025 | Gvoke Hypopen |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $41.28 | 2025 | Caplyta |
| Phathom Pharmaceuticals, INC. | $34.61 | 2024 | Voquezna |
| Inspire Medical Systems, INC. | $28.99 | 2025 | Inspire |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $28.25 | 2025 | Ohtuvayre |
| Vapotherm INC | $21.44 | 2022 | |
| Janssen Pharmaceuticals, INC | $21.35 | 2023 | Xarelto |
| Biohaven Pharmaceutical Holding Company LTD. | $19.56 | 2022 | |
| Azurity Pharmaceuticals, INC. | $15.91 | 2023 | Horizant |
| Merck Sharp & Dohme LLC | $13.90 | 2022 | |
| Genentech USA, INC. | $3.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cheryl Eldridge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.